SAB Biotherapeutics, Inc. (SABSW) stock

SABSWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SABS

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 4/30

$0.01+0.00 (+33.33%)

Close on Oct 20, 2026Market cap $304.80MP/E –Yield –

SAB Biotherapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

SAB Biotherapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in SAB Biotherapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-5.67 reverse split on Mar 29, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is SABSW.

Revenue growth-100.0% · median 15.6%

Advertisement
300 × 250